尽管诊断年龄更大,生存结局仍改善:英国单中心原发中枢神经系统淋巴瘤逐时代分析
该回顾性单中心研究分析英国诺丁汉大学医院1982至2020年四个十年间原发中枢神经系统淋巴瘤患者数据,按两个治疗时代分组:1982-2010年147例和2011-2020年125例。多因素分析显示第二时代以大剂量甲氨蝶呤为基础的诱导方案与更好总生存相关,且活检后14天内启动化疗和使用利妥昔单抗独立相关。
要点
- 第二时代诊断中位年龄更大,但3、6、12个月总生存率显著高于第一时代
- 第二时代以大剂量甲氨蝶呤为基础的诱导方案与总生存改善独立相关
- 活检后14天内启动化疗和使用利妥昔单抗独立关联更好生存
核心结论
- 尽管第二时代诊断年龄更大,原发中枢神经系统淋巴瘤患者生存结局仍显著改善。
- 及时启动治疗以及采用强化大剂量甲氨蝶呤和利妥昔单抗方案可能带来生存获益。
研究设计与样本
- 英国诺丁汉大学医院信托数据库四十年回顾性分析。
- 第一时代1982年1月1日至2010年12月31日147例,第二时代2011年1月1日至2020年7月31日125例。
主要发现
- 第二时代内活检后14天内启动化疗和使用利妥昔单抗独立关联更好总生存和无进展生存。
临床怎么用
- 对原发中枢神经系统淋巴瘤应尽早启动化疗,活检后14天内治疗与更好生存相关。
- 优先采用强化大剂量甲氨蝶呤为基础并联合利妥昔单抗的方案。
局限性
- 单中心回顾性研究,结果需多中心验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Observational studies with long-term follow-up of patients with primary central nervous system lymphoma (PCNSL) are scarce. Patient data over a period of four decades were retrospectively analysed from databases at Nottingham University Hospitals Trust, UK. The cohort was delineated by two distinct therapeutic eras; the first from 01/01/1982 to 31/12/2010 (n = 147) and the second 01/01/2011 to 31/07/2020 (n = 125). The median age at diagnosis was significantly older in the second era compared to the first (69 and 65 years respectively, P = 0·003). The 3-, 6- and 12-month overall survival (OS) rates in the second era were significantly higher compared to the first, at 85%, 77%, 62% versus 56%, 49%, 38% respectively (log-rank test P < 0·0001). On multivariate analysis, high-dose methotrexate (HD-MTX)-based induction protocols employed in the second era were associated with improved OS compared to those used in the first [hazard ratio (HR) 0·40, 95% confidence interval (CI) 0·28-0·57]. Within the second era, superior OS rates were seen with the use of intensive HD-MTX protocols (including consolidation with high-dose chemotherapy and autologous stem cell transplantation) compared to non-intensive HD-MTX schedules (HR 0·47, 95% CI 0·22-0·99). Initiating chemotherapy within 14 days of biopsy and use of rituximab were independently associated with improved OS and progression-free survival during the second era. These data suggest that prompt treatment initiation and use of intensive HD-MTX- and rituximab-based protocols have resulted in improved survival outcomes for patients.
引用
- Kaji FA, Martinez-Calle N, Bishton MJ, et al. Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. Br J Haematol. 2021. PMID: 34368948. doi:10.1111/bjh.17747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。